Design Concepts and Process Analysis for Transmuter Fuel Manufacturing: Quarterly Progress Report #2

This report discusses mainly the fabrication of inert matrix fuels. There are three fabrication routes to obtain inert matrix fuels (IMF). IMF is a dispersion-type fuel in which the actinide phase is distributed as a separate phase in a so called inert matrix. This concept has evolved as one of the most promising in the field of transmutation. The following section discusses each manufacturing route aside

The isolation and hybridization of DNA from Pseudomonas Aeruginosa PaG158

Thesis (B.S.) in Chemistry -- University of Illinois at Urbana-Champaign, 1988.Bibliography: leaves 36-37.Microfiche of typescript. [Urbana, Ill.]: Photographic Services, University of Illinois, U of I Library, [1988]. 2 microfiches (44 frames): negative

Studies of renal autoregulation in pancreatectomized and streptozotocin diabetic rats

Studies of renal autoregulation in pancreatectomized and streptozotocin diabetic rats. We studied renal autoregulation in pancreatectomized Munich-Wistar diabetic rats and in their sham-operated controls. In a second experiment we studied renal autoregulation in untreated and insulin treated streptozotocin diabetic Munich-Wistar rats and their nondiabetic controls. In the first experiment the diabetic rats had higher baseline renal blood flows (RBF). There was a fall in renal vascular resistance (RVR) and sustained RBF in both diabetic and control rats as renal perfusion pressures (RPP) was reduced from 130 and 110mm Hg. As RPP was reduced from 110 and 80mm Hg, there was no significant change in RVR in control rats and RBF began to fall. Below RPP of 80mm Hg RVR rose and RBF fell sharply in these rats. In contrast, there was a progressive fall in RVR as RPP was lowered to 60mm Hg in the diabetic rats and, thus, RBF was much better sustained in these animals. In the second experiment the plasma glucose level was 502 ± 52 mg/dl (X ± SD) in the untreated diabetic rats and only modestly reduced to 411 ± 49 mg/dl in the insulin treated animals. Untreated streptozotocin diabetic rats had moderately reduced and insulin-treated diabetic rats had mildly reduced baseline RVR and RBF. However, in these animals as in the pancreatectomized rats the increases in RVR noted in control rats at subautoregulatory RPPs were not seen. Thus, regardless of whether baseline RBFs were increased or decreased, diabetic rats sustained RBF at markedly reduced RPPs far more efficiently than did nondiabetic rats. The pathogenesis of these abnormalities in diabetic rats was not learned in these studies. However, it is likely that further study of autoregulation in diabetic rats could uncover factors influencing renal vascular tone which would be helpful in understanding the renal hemodynamic perturbations which may attend this experimental model

Modeling the decline of the Porcupine Caribou Herd, 1989-1998: the importance of survival vs. recruitment

The Porcupine caribou (Rangifer tarandus granti) herd increased from approximately 100 000 animals during the 1970s to 178 000 in 1989, then declined to 129 000 by 1998. Our objective was to model the dynamics of this herd and investigate the potential that lower calf recruitment, as was observed during 1991-1993, produced the observed population changes. A deterministic model was prepared using estimates of birth and survival rates that reproduced the pattern of population growth from 1971-1989. Then, parameters were changed to simulate effects of lower calf recruitment and adult survival. Reducing recruitment for 3 years caused an immediate reduction in population size, but the population began to recover in 5-6 years. Even a dramatic temporary reduction in recruitment did not explain the continuing decline after 1995. In contrast, a slight but persistent reduction in adult survival caused a decline that closely followed the observed pattern. This suggests that survival of adults, and perhaps calves, has declined since the late 1980s

К вопросу о значимости дозировки препаратов в ферментозаместительной терапии при болезни Фабри

Болезнь Фабри (БФ) – X-сцепленное заболевание, обусловленное мутациями в гене, кодирующем лизосомальную гидролазу α-галактозидазу А, при котором происходит прогрессирующее накопление в лизосомах глоботриаозилцерамида и связанных гликосфинголипидов. У пациентов мужского пола с классическим фенотипом болезни заболевание клинически манифестирует в детском или подростковом возрасте и характеризуется несколькими симптомами, в том числе нарушением почечной функции, цереброваскулярными осложнениями, сердечной недостаточностью и в конечном счете преждевременной смертью

VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study.

Background: Perioperative chemotherapy plus surgery is one recommended standard treatment for patients with resectable gastric and esophageal cancer. Even with a multimodality treatment more than half of patients will relapse following surgical resection. Patients who have a poor response to neoadjuvant chemotherapy and have an incomplete (R1) resection or have metastatic lymph nodes in the resection specimen (N+) are especially at risk of recurrence. Current clinical practice is to continue with the same chemotherapy in the adjuvant setting as before surgery. In the phase II randomized EORTC VESTIGE trial (NCT03443856), patients with high risk resected gastric or esophageal adenocarcinoma will be randomized to either adjuvant chemotherapy (as before surgery) or to immunotherapy with nivolumab and low dose ipilimumab (nivolumab 3 mg/kg IV Q2W plus Ipilimumab 1 mg/kg IV Q6W for 1 year). The primary endpoint of the study is disease free survival, with secondary endpoints of overall survival, safety and toxicity, and quality of life. This is an open label randomized controlled multi-center phase-2 superiority trial. Patients will be randomized in a 1:1 ratio to study arms. The trial will recruit 240 patients; recruitment commenced July 2019 and is anticipated to take 30 months. Detailed inclusion/exclusion criteria, toxicity management guidelines, and statistical plans for EORTC VESTIGE are described in the manuscript. Clinical Trial Registration: The trial is registered with www.ClinicalTrials.gov, identifier: NCT03443856

Means versus goals at the starting line: performance and conditions of effectiveness of entrepreneurial action

Various theoretical perspectives suggest that a means-oriented approach to new venture development can be a viable alternative to the conventional approach, which emphasizes predetermined goals, and that the former is favored by expert entrepreneurs. However, it is still unclear whether, and under which conditions, means-based action positively affects entrepreneurial performance and whether it would also be effective for novices. This study demonstrates the new venture performance impact of means orientation. We further contribute to various strands of entrepreneurship research by highlighting two moderating factors that are salient in the early-stage entrepreneurial process: opportunity recognition beliefs and process control practices